This site is intended for Healthcare professionals only.

AbbVie tops second quarter estimates, sets higher earnings target


AbbVie tops second quarter estimates, sets higher earnings target

AbbVie Inc on Friday topped Wall Street estimates for second-quarter profit and raised its yearly earnings forecast, led by stronger demand for top-selling drugs Humira and Imbruvica.

The drugmaker said sales of rheumatoid arthritis medicine Humira, which accounts for some two-thirds of AbbVie’s overall revenue, rose to $5.19 billion in the three months ended June 30. Six analysts polled by Thomson Reuters I/B/E/S had on average expected $5.18 billion.

Humira is the world’s best-selling prescription medicine, and AbbVie has aggressively tried to fend off any competition from rival drugmakers looking to make cheaper copies of the drug. The North Chicago, Illinois-based company has signed agreements with drug companies including Mylan to keep them from launching any Humira copies until 2023.

AbbVie’s Imbruvica cancer drug raked in second-quarter sales of $850 million, exceeding analysts’ estimates of $827.2 million.

AbbVie now expects 2018 adjusted earnings of between $7.76 and $7.86 per share, compared with an earlier expectation of between $7.66 and $7.76.

Excluding one-time items, AbbVie earned $2 per share, edging past analysts’ expectations of $1.97. Net earnings rose 3.6 percent to $1.98 billion or $1.26 per share.

Revenue rose about 19 percent to $8.28 billion. Analysts had expected $8.21 billion.

(Reporting by Tamara Mathias and Akanksha Rana in Bengaluru; Editing by Sai Sachin Ravikumar)



Source: REUTERS
0 comment(s) on AbbVie tops second quarter estimates, sets higher earnings target

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted